ArticleNature cardiovascular research2024
Identification of a non-canonical chemokine-receptor pathway suppressing regulatory T cells to drive atherosclerosis.
Article in Nature cardiovascular research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmacological and Genetic Targeting of Inflammatory Chemokine Receptors CCR1, CCR2, and CCR5 in Atherosclerosis: A Systematic Review and Meta-Analysis of Preclinical Studies.Journal of the American Heart Association · 2026Pooled it
- A Chemokine Profile Linked to Both Triglyceride-Rich Lipoproteins and Lipoprotein(a), But Not LDL, Is Associated With Cardiovascular Disease.JACC. Basic to translational science · 2026Article
- Nanomaterials-Based Immunotherapy for Atherosclerosis.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Monocyte Chemokines Enhance Atherosclerotic Plaque Necrosis After Bacterial Kidney Infection.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- CC Chemokines in Myocardial Fibrosis: Regulatory Networks of CCL17 and Emerging Therapeutic Implications.International journal of molecular sciences · 2026Review
- ChemR23 prevents phenotypic switching of vascular smooth muscle cells into macrophage-like foam cells in atherosclerosis.Cardiovascular research · 2026Article
- Markers of neuroinflammation in the CSF of patients with difficult to treat psychiatric disease.Frontiers in psychiatry · 2026Article
- Regulatory T Cells: Subtle and Promising Achilles' Heel of Psoriasis - Atherosclerosis Comorbidity.Mini reviews in medicinal chemistry · 2026Review
- CCL17 as an Inflammatory Biomarker Enhances Cardiovascular Risk Stratification: a Prospective Cohort Study.Journal of cardiovascular translational research · 2025Article
- Chemokine-receptor-guided B-cell immunity in cardiovascular disease.Basic research in cardiology · 2025Review
- SENP3 mediated DeSUMOylation of macrophage derived CCL17 accelerates atherosclerosis via regulation of Treg.Cell biology and toxicology · 2025Article
- Theranostic porphyrin nanoparticles identify atherosclerosis via multimodal imaging and elicit atheroprotective effects.Materials today. Bio · 2025Article
- Lipid metabolism-related inflammatory indices (LMIIs) and incident peripheral artery diseases (PAD) in patients with type 2 diabetes mellitus (T2DM): a multicohort study from China and the UK biobank.Cardiovascular diabetology · 2025Article
- Effects of Mytilus edulis derived plasmalogens against atherosclerosis via lipid metabolism and MAPK signaling pathway.NPJ science of food · 2025Article
- Article
- Metabolic and Immune Crosstalk in Cardiovascular Disease.Circulation research · 2025Review
- Single-cell dissection reveals immunosuppressive F13A1+ macrophage as a hallmark for multiple primary lung cancers.Clinical and translational medicine · 2024Article
- Targeting immune cell recruitment in atherosclerosis.Nature reviews. Cardiology · 2024Review
- Review
- Emerging Anti-Inflammatory COPD Treatments: Potential Cardiovascular Impacts.International journal of chronic obstructive pulmonary disease · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CCL17 is produced by conventional dendritic cells (cDCs), signals through CCR4 on regulatory T cells (Tregs), and drives atherosclerosis by suppressing Treg functions through yet undefined mechanisms. Here we show that cDCs from CCL17-deficient mice display a pro-tolerogenic phenotype and transcriptome that is not phenocopied in mice lacking its cognate receptor CCR4. In the plasma of CCL17-deficient mice, CCL3 was the only decreased cytokine/chemokine. We found that CCL17 signaled through CCR8 as an alternate high-affinity receptor, which induced CCL3 expression and suppressed Treg functions in the absence of CCR4. Genetic ablation of CCL3 and CCR8 in CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.